Glenna Mileson - 19 Jan 2023 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Reporting relationship: Chief Financial Officer
Issuer ticker: ATHA
Reported as of: 19 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jan 2023, 16:51:37 UTC
Prior SEC filing: 30 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ Glenna Mileson

Key filing fact

Glenna Mileson filed Form 4 for Athira Pharma, Inc. (ATHA) on 23 Jan 2023.

Key facts

This page summarizes Glenna Mileson's Form 4 filing for Athira Pharma, Inc. (ATHA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jan 2023, 16:51.

Change

Previous filing in this sequence was filed on 30 Dec 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATHA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +150,000
Change %
Price: $0.000000
Shares after: 150,000
Date: 19 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $3.37
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One thirty-sixth (1/36th) of the shares subject to the option will vest on February 19, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter.